



# New Experience with Transarterial Micro-Perfusion (TAMP)

**Khashayar Farsad, MD, PhD**

Associate Professor and Director of Research  
Dotter Department of Interventional Radiology  
Oregon Health and Science University  
Portland, OR







# Pancreatic Cancer




- 3<sup>rd</sup> leading cause of cancer death in the US (projected 2<sup>nd</sup> by 2030)
  - US new patients/yr: 54,000
  - US deaths/yr: 42,000
- Local disease = surgery (20% 5 year survival)
- Systemic disease = chemotherapy (6-11 mo median survival)
- Limited options for locally advanced pancreatic CA (LAPC)
  - >180 deg encasement of arteries, unresectable PV/SMV, no mets
  - 30% of patients
  - Limited Tx options, Chemo just like metastatic dz

# Locally-advanced pancreatic adenocarcinoma encasing SMA/hepatic artery





# RenovoCath™ (RenovoRx): Double balloon-occlusion catheter for transvascular drug delivery






# Ideal Case?



# Clinical Response with RenovoCath TACE vs. Historical Control

## Adenocarcinoma of the Pancreas




† Jiang X, Galettix P, Links M et al. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. *British Journal of Clinical Pharmacology*; 65:326-333

\*Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy. *Ann Oncol* 2008; 19:1592-9

# Subset analysis: ?Better outcomes with Radiation + Trans-Arterial Micro-Perfusion (TAMP)


Phase 1 Safety Study and follow up Registry Study demonstrated survival benefit **after** RenovoCath™ treatments






# Mechanism of action: Trans-Arterial Micro-Perfusion (TAMP) combined with radiation


Radiation reduces venous outflow  
by decreasing the microvasculature



Native vasculature  
Micro-vascular  
washout



Irradiated vasculature  
>Diffusion




**Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel  
Following Radiotherapy for LAPC (TIGeR-PaC)  
NCT03257033**

# TIGer-PaC Trial

- Randomized multi-center, open label trial for LAPC
- Compares intra-arterial gemcitabine vs IV gem/nab-paclitaxel
- Primary objective: Overall Survival
- Secondary objectives: PFS, Toxicities, QOL
- Goal: 298 enrolled patients, 208 randomized patients

# TIGeR-PaC trial flow chart



**IV/XRT induction  
(all patients)**

**IV cycles x 4 mo**

**IA cycles x 4 mo**

**IV Rx continuation  
(all patients)**

# Thank You!

